Ventyx Biosciences (VTYX) Set to Announce Quarterly Earnings on Thursday

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) is set to release its earnings data after the market closes on Thursday, May 9th. Analysts expect Ventyx Biosciences to post earnings of ($0.67) per share for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its earnings results on Tuesday, February 27th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.08. During the same period in the previous year, the firm posted ($0.62) EPS. On average, analysts expect Ventyx Biosciences to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ventyx Biosciences Trading Down 1.2 %

VTYX stock traded down $0.06 during trading on Friday, hitting $4.85. 853,087 shares of the company's stock were exchanged, compared to its average volume of 3,491,605. The business has a 50-day moving average price of $6.08 and a two-hundred day moving average price of $5.07. The stock has a market capitalization of $341.93 million, a price-to-earnings ratio of -1.47 and a beta of 0.48. Ventyx Biosciences has a 52-week low of $1.87 and a 52-week high of $40.58.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on VTYX. Wells Fargo & Company upgraded Ventyx Biosciences from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $7.00 to $16.00 in a research note on Tuesday, March 12th. Oppenheimer upgraded Ventyx Biosciences from a "market perform" rating to an "outperform" rating and set a $12.00 price objective for the company in a research note on Tuesday, March 12th. Canaccord Genuity Group reduced their price objective on Ventyx Biosciences from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Wednesday, March 13th. Finally, Lifesci Capital upgraded Ventyx Biosciences from a "market perform" rating to an "outperform" rating in a research note on Wednesday, February 28th. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $21.75.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.